Covidien Gains Barrett’s Esophagus Ablation Device Via Barrx Acquisition
Deal worth $325 million bolsters Covidien’s energy-based product offerings with Barrx Medical’s radiofrequency energy-based HaloFlex system for preventing esophageal cancer.
Deal worth $325 million bolsters Covidien’s energy-based product offerings with Barrx Medical’s radiofrequency energy-based HaloFlex system for preventing esophageal cancer.